期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 44, 期 1, 页码 69-73出版社
ELSEVIER
DOI: 10.1016/j.ijantimicag.2014.03.007
关键词
Clostridium difficile; High-throughput screen; Antibiotic discovery; Small-molecule library
资金
- National Institutes of Health [NIH U54 A1 057168, NIH R01 AI068942]
- Global Alliance for TB Drug Development
Clostridium difficile, a highly drug-resistant Gram-positive, spore-forming bacterium, remains a leading cause of hospital-acquired diarrhoea and antibiotic-associated colitis. Clinically, only a handful of antibiotics are used for treating C. difficile infection (CDI), suggesting a necessity for the development of new treatment options. Here we performed a high-throughput screen of 2000 drug-like compounds for inhibition of C. difficile. From this screen, one compound, 5-nitro-1,10-phenanthroline (5-NP), showed potent bactericidal effects in vitro. In addition, this compound displayed high potency towards other Clostridium spp. as well as Mycobacterium bovis but not towards other tested Gram-positive and Gram-negative bacteria. Furthermore, we show that this inhibition may proceed through a metal chelation-dependent mechanism. More importantly, preliminary evidence suggests moderate efficacy for this compound in treating CDI in a murine infection model. These results present a possible basis for the further development of this compound as an antibiotic treatment for CDI. (C) 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据